- Report
- April 2025
- 175 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- April 2025
- 175 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- April 2025
- 175 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- December 2025
- 190 Pages
Global
From €5142EUR$5,850USD£4,489GBP
- Report
- December 2025
- 196 Pages
Global
From €5142EUR$5,850USD£4,489GBP
- Report
- December 2025
- 197 Pages
Global
From €5142EUR$5,850USD£4,489GBP
- Report
- September 2025
- 250 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- September 2025
- 250 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- September 2025
- 250 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- February 2025
- 200 Pages
Global
From €3946EUR$4,490USD£3,446GBP
- Report
- September 2025
- 149 Pages
Global
From €2240EUR$2,549USD£1,956GBP
€2636EUR$2,999USD£2,301GBP
- Report
- October 2025
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
- Report
- February 2025
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
€4263EUR$4,850USD£3,722GBP
- Report
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,140GBP
- Report
- June 2025
- 150 Pages
Global
From €2372EUR$2,699USD£2,071GBP
- Report
- June 2025
- 150 Pages
Global
From €2372EUR$2,699USD£2,071GBP
- Report
- October 2025
- 160 Pages
Global
From €2951EUR$3,358USD£2,577GBP
€3472EUR$3,950USD£3,031GBP
- Report
- August 2025
- 150 Pages
Global
From €2951EUR$3,358USD£2,577GBP
€3472EUR$3,950USD£3,031GBP
- Report
- November 2025
- 140 Pages
Global
From €3623EUR$4,123USD£3,164GBP
€4263EUR$4,850USD£3,722GBP
- Report
- July 2025
- 140 Pages
Global
From €3623EUR$4,123USD£3,164GBP
€4263EUR$4,850USD£3,722GBP

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients.
IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more